We are pleased to serve as sole bookrunner for AirSculpt’s Follow-On Offering. Learn more about us and see all of our transactions online at https://lnkd.in/eBA_y88n
About us
Leerink Partners is a highly specialized healthcare investment bank with a legacy of excellence in the financial industry. The firm’s experienced team delivers innovative advisory solutions, capital raising expertise, and unique insights to empower clients to achieve their strategic objectives. Since inception the firm has advised on $65 billion, helped clients raise over $170 billion and has established itself as a trusted partner to healthcare companies and their investors. The firm is a broker-dealer registered with the United States Securities and Exchange Commission and a member of the Financial Industry Regulatory Authority.
- Website
-
https://www.leerink.com/
External link for Leerink Partners
- Industry
- Investment Banking
- Company size
- 201-500 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Specialties
- healthcare, life science, capital markets, mergers and acquisition, corporate finance, and equity research
Locations
Employees at Leerink Partners
Updates
-
We are pleased to serve as joint bookrunning manager for Insmed’s Upsized $750 Million Follow-On Offering. Learn more about us and see all of our transactions online at https://lnkd.in/eBA_y88n
-
-
We are pleased to serve as exclusive financial advisor for Cogent Biosciences’ $400 Million Term Loan Facility. Learn more about us and see all of our transactions online at https://lnkd.in/eBA_y88n
-
-
We’re proud to announce that Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, has been appointed to the US Congressional Budget Office’s Panel of Health Advisers. This prestigious panel brings together experts in health policy to advise the CBO on its analyses and the latest research. Congratulations on this well-deserved recognition! Learn more: https://lnkd.in/eaQXNSAK
-
-
We are pleased to serve as joint bookrunner for Merus’ $300 Million Follow-On Offering. Learn more about us and see all of our transactions online at https://lnkd.in/eBA_y88n
-
-
We are pleased to serve as joint bookrunner for Trevi Therapeutics’ $100 Million Follow-On Offering. Learn more about us and see all of our transactions online at https://lnkd.in/eBA_y88n
-
-
We are pleased to serve as sole bookrunner for Xilio Therapeutics’ $50 Million Follow-On Offering. Learn more about us and see all of our transactions online at https://lnkd.in/eBA_y88n
-
-
We are pleased to serve as sole bookrunner for Immunic Therapeutics’ $65 Million Follow-On Offering. Learn more about us and see all of our transactions online at https://lnkd.in/eBA_y88n
-
-
Postpartum mothers with depression now have a novel oral treatment option. Our latest Leerink Center for Pharmacoeconomics (CPE) Exclusive explores Zurzuvae® and how the impact of postpartum depression reaches far beyond the healthcare system—and the mother herself. Read the full report here: https://lnkd.in/egZ8-bpP The Leerink Center for Pharmacoeconomics is a division of MEDACorp which is an affiliate of Leerink Partners.
-
-
We are pleased to serve as sole agent for Contineum Therapeutics’s $75 Million At-The-Market (ATM) Facility. Learn more about us and see all of our transactions online at https://lnkd.in/eBA_y88n
-